

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 15th day of November 2004.

(Signature of person mailing)  
 Kelley D. Surprenant

(Signature of person mailing)  
Kelley D. Surprenant

(Typed or printed name of person)

IN RE APPLICATION OF: Nizal Chandrakumar, et al. :

APPLICATION NO.: 10/664,229 : Examiner: Peter G. O'Sullivan

FILING DATE: September 17, 2003 : Group Art Unit: 1621

TITLE: Aromatic Liver X-Receptor Modulators

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references, cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 C.F.R. 1.17(p). The Commissioner is further authorized to charge any additional fees, which may be required under 37 C.F.R. 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date: November 15, 2004

Respectfully submitted,


A handwritten signature in dark ink, appearing to read "Lisa Samuels", is written over a horizontal line.

Lisa A. Samuels

Attorney for Applicant(s)

Reg. No. 43,080

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 686-0349



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC27861//01	SERIAL NO. 10/664,229
	APPLICANT Nizal Chandrakumar, et al.	
	FILING DATE September 17, 2003	GROUP 1621

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	03	0	0	2	1	1	8	1/9/03	International	A61K	31/47		

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

			FUKUCHI, J., et al., "Transcriptional Regulation of Farnesyl Pyrophosphate Synthase by Liver X Receptors", Steroids, 2003, Pages 685-691, Volume 68 (7-8), Elsevier Science B.V.
			LUND, E.G., et al., "Liver X Receptor Agonists as Potential Therapeutic Agents for Dyslipidemia and Atherosclerosis", Arteriosclerosis, Thrombosis, and Vascular Biology, July 2003, pages 1169-1177, Volume 23(7), Lippincott Williams & Wilkins
			SONG, C., et al., "Auto-Oxidized Cholesterol Sulfates are Antagonistic Ligands of Liver X Receptors: Implications for the Development and Treatment of Atherosclerosis", Steroids, 2001, pages 473-479, Volume 66(6), Elsevier Science, Inc.
			STULNIG, T.M., et al., "Liver X Receptors Downregulate 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 Expression and Activity", Diabetes, 2002, pages 2426-2433, Volume 51(8), American Diabetes Association
			WHITNEY, K.D., et al., "Regulation of Cholesterol Homeostasis by the Liver X Receptors in the Central Nervous System", Molecular Endocrinology, June 2002, pages 1378-1385, Volume 16(6), Endocrine Society

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.